+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

La Merie Publishing - Market Research Reports

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie publish reports, offer R&D database access, and prepare tailor-made custom reports on a fee-for-service basis.

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis - Product Thumbnail Image

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

  • Report
  • July 2022
  • 60 Pages
From
Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis - Product Thumbnail Image

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

  • Report
  • July 2022
  • 263 Pages
From
ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis - Product Thumbnail Image

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

  • Report
  • June 2022
  • 115 Pages
From
Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities - Product Thumbnail Image

Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities

  • Report
  • May 2022
  • 32 Pages
From
Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities - Product Thumbnail Image

Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities

  • Report
  • May 2022
  • 50 Pages
From
Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies, Pipeline, Partnering and Financing - Product Thumbnail Image

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies, Pipeline, Partnering and Financing

  • Report
  • March 2022
  • 553 Pages
From
Masked Antibodies & Cytokines as Prodrugs: A Landscape Analysis of Stakeholders, Technologies, Pipelines, Business and Financing from An Industry Perspective - Product Thumbnail Image

Masked Antibodies & Cytokines as Prodrugs: A Landscape Analysis of Stakeholders, Technologies, Pipelines, Business and Financing from An Industry Perspective

  • Report
  • October 2021
  • 433 Pages
From
Vectorized Antibodies for In Vivo Expression by DNA and mRNA: A Landscape Analysis Of Stakeholders, Technologies, Targets, Business and Financing from an Industry Perspective - Product Thumbnail Image

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: A Landscape Analysis Of Stakeholders, Technologies, Targets, Business and Financing from an Industry Perspective

  • Report
  • July 2021
  • 259 Pages
From
DNA Vaccines for Cancer, Infectious & Other Diseases: A Competitor Analysis - Product Thumbnail Image

DNA Vaccines for Cancer, Infectious & Other Diseases: A Competitor Analysis

  • Report
  • January 2019
  • 72 Pages
From
T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis - Product Thumbnail Image

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis

  • Report
  • June 2019
  • 463 Pages
From
Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases - Product Thumbnail Image

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

  • Report
  • June 2019
  • 121 Pages
From
Report Package: Bispecific Antibodies - Product Thumbnail Image

Report Package: Bispecific Antibodies

  • Report
  • July 2019
From
RNA-Targeted Small Molecules 2019: A Landscape Analysis of Companies, Technologies, Targets, Investors and Partners from an Industry Perspective - Product Thumbnail Image

RNA-Targeted Small Molecules 2019: A Landscape Analysis of Companies, Technologies, Targets, Investors and Partners from an Industry Perspective

  • Report
  • September 2019
  • 223 Pages
From
Competitor Analysis: RORgamma Antagonists and Agonists - Product Thumbnail Image

Competitor Analysis: RORgamma Antagonists and Agonists

  • Report
  • September 2019
  • 28 Pages
From
Competitor Analysis: TGF-beta/Receptor Inhibitors - Product Thumbnail Image

Competitor Analysis: TGF-beta/Receptor Inhibitors

  • Report
  • September 2019
  • 59 Pages
From
Competitor Analysis: KRAS Inhibitors - Product Thumbnail Image

Competitor Analysis: KRAS Inhibitors

  • Report
  • October 2019
  • 35 Pages
From
Report Package: “Drug the Undruggable” Technologies - Product Thumbnail Image

Report Package: “Drug the Undruggable” Technologies

  • Report
  • May 2020
From
Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: A Landscape Analysis of Companies, Technologies, Targets, Investors and Partners From an Industry Perspective - Product Thumbnail Image

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: A Landscape Analysis of Companies, Technologies, Targets, Investors and Partners From an Industry Perspective

  • Report
  • May 2020
  • 195 Pages
From
TCR Engineered T-Cell Therapy 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals - Product Thumbnail Image

TCR Engineered T-Cell Therapy 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals

  • Report
  • May 2018
  • 294 Pages
From
Report Package: TCR-Based Antibody and T-Cell Immunotherapy - Product Thumbnail Image

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

  • Report
  • May 2018
  • 546 Pages
From
Loading Indicator